Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 30;23(19):11561.
doi: 10.3390/ijms231911561.

Practical Significance of Biomarkers in Axial Spondyloarthritis: Updates on Diagnosis, Disease Activity, and Prognosis

Alexandra-Diana Diaconu  1 , Alexandr Ceasovschih  2   3 , Victorița Șorodoc  2   3 , Cristina Pomîrleanu  1   3 , Cătălina Lionte  2   3 , Laurențiu Șorodoc  2   3 , Codrina Ancuța  1   3
Affiliations
Review

Practical Significance of Biomarkers in Axial Spondyloarthritis: Updates on Diagnosis, Disease Activity, and Prognosis

Alexandra-Diana Diaconu et al. Int J Mol Sci. .

Abstract

Axial spondyloarthritis (axSpA) is a chronic inflammatory disease that can lead to ankylosis by secondary ossification of inflammatory lesions, with progressive disability and a significant impact on quality of life. It is also a risk factor for the occurrence of comorbidities, especially cardiovascular diseases (CVDs), mood disorders, osteoporosis, and malignancies. Early diagnosis and treatment are needed to prevent or decrease functional decline and to improve the patient's prognosis. In respect of axSpA, there is an unmet need for biomarkers that can help to diagnose the disease, define disease activity and prognosis, and establish personalized treatment approaches. The aim of this review was to summarize the available information regarding the most promising biomarkers for axSpA. We classified and identified six core categories of biomarkers: (i) systemic markers of inflammation; (ii) molecules involved in bone homeostasis; (iii) HLA-B27 and newer genetic biomarkers; (iv) antibody-based biomarkers; (v) microbiome biomarkers; and (vi) miscellaneous biomarkers. Unfortunately, despite efforts to validate new biomarkers, few of them are used in clinical practice; however, we believe that these studies provide useful data that could aid in better disease management.

Keywords: HLA-B27; antibody-based biomarkers; axial spondyloarthritis; diagnosis; disease activity; microbiome biomarkers; molecules involved in bone homeostasis; newer genetic biomarkers; prognosis; systemic markers of inflammation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Biomarkers significance in axial spondiloarthtitis.
See this image and copyright information in PMC

References

    1. Firestein G.S., Budd R.C., Koretzky G., Gabriel S.E., McInnes I.B., O’Dell J.R. Firestein & Kelley’s Textbook of Rheumatology. 11th ed. Volume 2. Elsevier; Amsterdam, The Netherlands: 2020. p. 1307.
    1. Cardelli C., Monti S., Terenzi R., Carli L. One year in review 2021: Axial spondyloarthritis. Clin. Exp. Rheumatol. 2021;39:1272–1281. doi: 10.55563/clinexprheumatol/jlyd1l. - DOI - PubMed
    1. Walsh J.A., Magrey M. Clinical Manifestations and Diagnosis of Axial Spondyloarthritis. J. Clin. Rheumatol. 2021;27:e547–e560. doi: 10.1097/RHU.0000000000001575. - DOI - PMC - PubMed
    1. Ancuta C., Pomirleanu C. Principii de Diagnostic si Tratament in Reumatologie. 2nd ed. Universitatea de Medicină și Farmacie „Grigore T. Popa” din Iași; Iasi, Romania: 2019. p. 177.
    1. Califf R.M. Biomarker definitions and their applications. Exp. Biol. Med. 2018;243:213–221. doi: 10.1177/1535370217750088. - DOI - PMC - PubMed